Intellia Therapeutics (NTLA) has just wrapped enrollment in MAGNITUDE-2, its Phase 3 trial of CRISPR therapy nex-z for hereditary transthyretin amyloidosis with polyneuropathy, drawing fresh attention...
Source LinkIntellia Therapeutics (NTLA) has just wrapped enrollment in MAGNITUDE-2, its Phase 3 trial of CRISPR therapy nex-z for hereditary transthyretin amyloidosis with polyneuropathy, drawing fresh attention...
Source Link
Comments